PMLiVE
90 FOLLOWERS
PMLiVE.com is the online home to PME, Communiqué, and The Directory. The platform offers the latest pharma news, analysis, jobs, and events, including the annual Pharmaceutical Market Excellence Awards (PMEAs) and Communiqué Awards.
PMLiVE
15h ago
Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ten years ..read more
PMLiVE
15h ago
The company combines machine learning, data generation and therapeutic product development ..read more
PMLiVE
18h ago
The incidence of neuroendocrine tumours has increased over the past several decades ..read more
PMLiVE
18h ago
The type 2 RAF inhibitor is the first and only one approved in the US to treat this patient population ..read more
PMLiVE
18h ago
With 14 million people in Europe expected to suffer from Alzheimer’s and other forms of dementia by 2030, the race is on to find a treatment to not only slow its course, but even prevent the development of the disease ..read more
PMLiVE
2d ago
The deal includes an MRGPRX2 antagonist with the potential to treat multiple mast cell-mediated diseases ..read more
PMLiVE
2d ago
The factor D inhibitor has been authorised for use alongside the company’s complement C5 inhibitors ..read more
PMLiVE
2d ago
NMIBC accounts for up to 80% of bladder cancer cases, the tenth most commonly diagnosed cancer globally ..read more
PMLiVE
2d ago
AD is the most common form of dementia, which affects around 55 million people globally ..read more